This company has been marked as potentially delisted and may not be actively trading. Capstar Special Purpose Acquisition (CPSR) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsOwnershipTrendsBuy This Stock CPSR vs. MENS, MOR, GMTX, CALT, ZYME, SBTX, MBX, AVTE, NLTX, and CYBNShould you be buying Capstar Special Purpose Acquisition stock or one of its competitors? The main competitors of Capstar Special Purpose Acquisition include Jyong Biotech (MENS), MorphoSys (MOR), Gemini Therapeutics (GMTX), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), and Cybin (CYBN). Capstar Special Purpose Acquisition vs. Its Competitors Jyong Biotech MorphoSys Gemini Therapeutics Calliditas Therapeutics AB (publ) Zymeworks Silverback Therapeutics MBX Biosciences Aerovate Therapeutics Neoleukin Therapeutics Cybin Capstar Special Purpose Acquisition (NYSE:CPSR) and Jyong Biotech (NASDAQ:MENS) are both pharmaceutical preparations industry companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership. Is CPSR or MENS more profitable? Company Net Margins Return on Equity Return on Assets Capstar Special Purpose AcquisitionN/A N/A N/A Jyong Biotech N/A N/A N/A Do insiders and institutionals hold more shares of CPSR or MENS? 64.9% of Capstar Special Purpose Acquisition shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has better valuation & earnings, CPSR or MENS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCapstar Special Purpose AcquisitionN/AN/A-$15.30MN/AN/AJyong BiotechN/AN/AN/AN/AN/A Does the media refer more to CPSR or MENS? In the previous week, Jyong Biotech had 3 more articles in the media than Capstar Special Purpose Acquisition. MarketBeat recorded 3 mentions for Jyong Biotech and 0 mentions for Capstar Special Purpose Acquisition. Jyong Biotech's average media sentiment score of 0.54 beat Capstar Special Purpose Acquisition's score of 0.00 indicating that Jyong Biotech is being referred to more favorably in the news media. Company Overall Sentiment Capstar Special Purpose Acquisition Neutral Jyong Biotech Positive SummaryJyong Biotech beats Capstar Special Purpose Acquisition on 2 of the 3 factors compared between the two stocks. Get Capstar Special Purpose Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for CPSR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CPSR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CPSR vs. The Competition Export to ExcelMetricCapstar Special Purpose AcquisitionPharmaceutical Preparations IndustryMedical SectorNYSE ExchangeMarket Cap$847.15M$820.93M$5.74B$20.88BDividend YieldN/A4.84%4.53%3.60%P/E RatioN/A1.1430.4328.32Price / SalesN/A25.74392.4152.52Price / CashN/A19.5637.0323.77Price / Book-20.816.618.955.19Net Income-$15.30M-$4.93M$3.26B$992.10M Capstar Special Purpose Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CPSRCapstar Special Purpose AcquisitionN/A$24.560.0%N/A+276.1%$847.15MN/A0.002MENSJyong BiotechN/A$40.00-1.0%N/AN/A$3.04BN/A0.0031MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730Positive NewsGMTXGemini TherapeuticsN/A$58.59+1.0%N/A+16.5%$2.54BN/A-58.5930CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks1.777 of 5 stars$13.23+6.4%$21.43+62.0%+31.7%$988.06M$122.87M-8.76460SBTXSilverback TherapeuticsN/A$16.38-6.4%N/A-7.4%$590.63MN/A-6.7783News CoveragePositive NewsHigh Trading VolumeMBXMBX Biosciences2.5715 of 5 stars$12.86+2.6%$37.63+192.6%N/A$429.33MN/A-2.8136News CoverageAVTEAerovate TherapeuticsN/A$7.40-1.2%N/A-88.4%$214.49MN/A-2.4720High Trading VolumeNLTXNeoleukin TherapeuticsN/A$20.35-4.1%N/A-45.0%$191.25MN/A-6.5490High Trading VolumeCYBNCybin2.4601 of 5 stars$7.67+0.5%$85.00+1,008.9%N/A$180.87MN/A-1.7550Trending NewsAnalyst Revision Related Companies and Tools Related Companies Jyong Biotech Competitors MorphoSys Competitors Gemini Therapeutics Competitors Calliditas Therapeutics AB (publ) Competitors Zymeworks Competitors Silverback Therapeutics Competitors MBX Biosciences Competitors Aerovate Therapeutics Competitors Neoleukin Therapeutics Competitors Cybin Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CPSR) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capstar Special Purpose Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capstar Special Purpose Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access